Latest Stories
1 Small-Cap Stock to Consider Right Now and 2 We Ignore
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
3 Stocks Under $10 with Warning Signs
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.
1 Stock Under $50 with Solid Fundamentals and 2 Facing Challenges
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
3 Reasons to Sell WABC and 1 Stock to Buy Instead
Over the past six months, Westamerica Bancorporation’s shares (currently trading at $46.46) have posted a disappointing 5.5% loss, well below the S&P 500’s 13.7% gain. This may have investors wondering how to approach the situation.
3 Big Reasons to Love Skyward Specialty Insurance (SKWD)
What a brutal six months it’s been for Skyward Specialty Insurance. The stock has dropped 24.7% and now trades at $46.60, rattling many shareholders. This might have investors contemplating their next move.
3 Reasons to Sell PESI and 1 Stock to Buy Instead
Perma-Fix has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 10.8% to $11.25 per share while the index has gained 13.7%.
3 Reasons to Avoid EXPD and 1 Stock to Buy Instead
Expeditors’s 22.7% return over the past six months has outpaced the S&P 500 by 9%, and its stock price has climbed to $139.22 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
3 Reasons to Sell LFST and 1 Stock to Buy Instead
LifeStance Health Group trades at $6.18 per share and has stayed right on track with the overall market, gaining 8.9% over the last six months. At the same time, the S&P 500 has returned 13.7%.
BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings?
Over the past six months, BioMarin Pharmaceutical’s stock price fell to $51.76. Shareholders have lost 11.5% of their capital, which is disappointing considering the S&P 500 has climbed by 13.7%. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
3 Reasons LGIH is Risky and 1 Stock to Buy Instead
Over the past six months, LGI Homes’s stock price fell to $44.28. Shareholders have lost 15.8% of their capital, which is disappointing considering the S&P 500 has climbed by 13.7%. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.